U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07282600) titled 'A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes' on Dec. 05.
Brief Summary: The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Overweight
Obesity
Intervention:
DRUG: Eloralintide
Administered SC
DRUG: Placebo
Administered SC
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Eli Lilly and Company
Published by H...